BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/12/2016 1:04:00 PM | Browse: 817 | Download: 1350
 |
Received |
|
2015-11-30 08:04 |
 |
Peer-Review Started |
|
2015-11-30 08:09 |
 |
To Make the First Decision |
|
2015-12-16 09:28 |
 |
Return for Revision |
|
2015-12-16 15:02 |
 |
Revised |
|
2015-12-30 22:16 |
 |
Second Decision |
|
2016-01-06 08:24 |
 |
Accepted by Journal Editor-in-Chief |
|
2016-01-08 14:20 |
 |
Accepted by Executive Editor-in-Chief |
|
2016-01-18 10:49 |
 |
Articles in Press |
|
2016-01-18 10:49 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
2016-02-24 02:32 |
 |
Typeset the Manuscript |
|
2016-03-18 12:57 |
 |
Publish the Manuscript Online |
|
2016-04-03 18:51 |
ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Basic Study |
Article Title |
Norcantharidin combined with ABT-737 for hepatocellular carcinoma: Therapeutic effects and molecular mechanisms
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Jing Ren, Gang Li, Wen Zhao, Ling Lin and Tao Ye |
Funding Agency and Grant Number |
|
Corresponding Author |
Tao Ye, MD, Department of Oncology, Minhang Hospital, Fudan University, No. 170 Xinsong Road, Minhang District, Shanghai 201199,
China. yaplter@vip.sina.com |
Key Words |
Norcantharidin; Hepatocellular carcinoma cell; Mcl-1 |
Core Tip |
The effects of ABT-737 and norcantharidin (NCTD) alone or in combination on HepG2 and SMMC-7721 cells were tested by methyl thiazolyl tetra-zolium, Western blot and flow cytometry. We found that as the concentration of NCTD increased, the cell proliferation inhibition rate gradually decreased; and the treatment effect of ABT-737 1-3 μm combined with NCTD on cell proliferation inhibition was stronger than that of ABT-737 alone (p < 0.05). The effect on inducing apoptosis in HepG2 and SMMC-7721 cells with the treatment of ABT-737 combined with NCTD for 48 h was greater than that of ABT-737 or NCTD alone (p < 0.05). NCTD combined with ABT-737 has a positive role in the treatment of HCC. |
Publish Date |
2016-04-03 18:51 |
Citation |
Ren J, Li G, Zhao W, Lin L, Ye T. Norcantharidin combined with ABT-737 for hepatocellular carcinoma: Therapeutic effects and molecular mechanisms. World J Gastroenterol 2016; 22(15): 3962-3968 |
URL |
http://www.wjgnet.com/1007-9327/full/v22/i15/3962.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v22.i15.3962 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345